A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to
determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while
on the treatment. This study evaluates the safety of these drug combinations, which include
an experimental protease inhibitor (PI), amprenavir.
Despite the success that many patients have had with PI treatment regimens, there is still a
possibility that patients receiving PIs may continue to have high HIV blood levels. Because
of this possibility, alternative drug combinations containing PIs are being studied. It
appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in
patients with prior PI treatment experience.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)